Irene Baccelli
Overview
Explore the profile of Irene Baccelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, et al.
Blood
. 2024 Mar;
143(26):2735-2748.
PMID: 38518105
Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates in children but are based on...
2.
Ligeron C, Saenz J, Evrard B, Drouin M, Merieau E, Mary C, et al.
J Immunol
. 2024 Feb;
212(7):1178-1187.
PMID: 38353642
The inflammatory response is a key mechanism for the elimination of injurious agents but must be tightly controlled to prevent additional tissue damage and progression to persistent inflammation. C-type lectin...
3.
Poirier N, Baccelli I, Belarif L, Abes R, Teppaz G, Mary C, et al.
J Immunol
. 2023 Feb;
210(6):753-763.
PMID: 36734626
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It is a strict antagonist of the IL-7R pathway, is not internalized by...
4.
Drouin M, Saenz J, Gauttier V, Evrard B, Teppaz G, Pengam S, et al.
Sci Adv
. 2022 Nov;
8(46):eabo7621.
PMID: 36399563
Tumors exploit numerous immune checkpoints, including those deployed by myeloid cells to curtail antitumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead...
5.
Krosl J, Bordeleau M, Moison C, MacRae T, Boivin I, Mayotte N, et al.
Blood Adv
. 2021 Nov;
6(2):509-514.
PMID: 34731885
Cholesterol homeostasis has been proposed as one mechanism contributing to chemoresistance in AML and hence, inclusion of statins in therapeutic regimens as part of clinical trials in AML has shown...
6.
Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella J, Corneau S, et al.
Cancer Cell
. 2019 Jul;
36(1):84-99.e8.
PMID: 31287994
To identify therapeutic targets in acute myeloid leukemia (AML), we chemically interrogated 200 sequenced primary specimens. Mubritinib, a known ERBB2 inhibitor, elicited strong anti-leukemic effects in vitro and in vivo....
7.
Simon L, Lavallee V, Bordeleau M, Krosl J, Baccelli I, Boucher G, et al.
Clin Cancer Res
. 2017 Sep;
23(22):6969-6981.
PMID: 28855357
-mutated () acute myeloid leukemia (AML) is associated with adverse outcome, highlighting the urgent need for a better genetic characterization of this AML subgroup and for the design of efficient...
8.
Lavallee V, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, et al.
Nat Genet
. 2015 Aug;
47(9):1030-7.
PMID: 26237430
Using next-generation sequencing of primary acute myeloid leukemia (AML) specimens, we identified to our knowledge the first unifying genetic network common to the two subgroups of KMT2A (MLL)-rearranged leukemia, namely...
9.
Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, et al.
Cancer Discov
. 2015 Feb;
5(5):506-19.
PMID: 25716347
Unlabelled: Regulatory pathways that drive early hematogenous dissemination of tumor cells are insufficiently defined. Here, we used the presence of disseminated tumor cells (DTC) in the bone marrow to define...
10.
Hofner T, Eisen C, Klein C, Rigo-Watermeier T, Goeppinger S, Jauch A, et al.
Stem Cell Reports
. 2015 Feb;
4(3):503-18.
PMID: 25702639
Methods to isolate and culture primary prostate epithelial stem/progenitor cells (PESCs) have proven difficult and ineffective. Here, we present a method to grow and expand both murine and human basal...